Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15;13(20):6132.
doi: 10.3390/jcm13206132.

Postoperative Outcomes of PreserFlo MicroShunt in Patients with Exfoliation Glaucoma

Hiroyuki Wakuda  1 , Ryota Aoki  1 , Shunsuke Nakakura  1
Affiliations

Postoperative Outcomes of PreserFlo MicroShunt in Patients with Exfoliation Glaucoma

Hiroyuki Wakuda et al. J Clin Med. .

Abstract

Objectives: This study aimed to evaluate the postoperative outcomes of the PreserFlo MicroShunt in Asian patients with exfoliation glaucoma. Methods: We used the Kaplan-Meier method to analyze 29 eyes of 29 patients with exfoliation glaucoma (mean age: 80.7 ± 8.3 years; 16 males; 24 eyes with intraocular lens implants; preoperative intraocular pressure [IOP]: 32.5 ± 9.3 mmHg; preoperative antiglaucoma medications: 3.4 ± 1.0; Asian ethnicity: 100%) who underwent PreserFlo MicroShunt surgery alone at Saneikai Tsukazaki Hospital from November 2022 to November 2023. The criteria for survival were a reduction in IOP of ≥20%, no additional glaucoma surgery, and IOP of 5-21 mmHg (condition 1), 5-18 mmHg (condition 2), and 5-15 mmHg (condition 3). Needling and glaucoma eye drops were considered qualified successes. Results: The mean follow-up period was 27.9 weeks, with a reoperation rate of 31% (9 cases). The complete and qualified success survival rates at 24 weeks were 56%, 52%, and 49%, and 67%, 59%, and 53% for conditions 1-3, respectively. The complete and qualified success survival rates at 48 weeks were 47%, 43%, and 45%, and 52%, 46%, and 48% for conditions 1-3, respectively. Conclusions: The postoperative outcomes of the PreserFlo MicroShunt in Asian patients with exfoliation glaucoma demonstrated an approximate 50% success rate at both 24 and 48 weeks, with a reoperation rate of approximately 30%. Caution is warranted when performing PreserFlo MicroShunt in patients with exfoliation glaucoma.

Keywords: exfoliation glaucoma; glaucoma surgery; innfocus; microshunt; open-angle glaucoma; preserflo; pseudoexfoliation glaucoma; subconjunctival filtration surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of each condition. (a) complete success, condition 1; (b) complete success, condition 2; (c) complete success, condition 3; (d) qualified success, condition 1, (e) qualified success, condition 2; (f) qualified success, condition 3.
See this image and copyright information in PMC

References

    1. Friedman D.S., Wolfs R.C., O’Colmain B.J., Klein B.E., Taylor H.R., West S., Leske M.C., Mitchell P., Congdon N., Kempen J., et al. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004;122:532–538. doi: 10.1001/archopht.122.4.532. - DOI - PMC - PubMed
    1. Pascolini D., Mariotti S.P. Global estimates of visual impairment: 2010. Br. J. Ophthalmol. 2012;96:614–618. doi: 10.1136/bjophthalmol-2011-300539. - DOI - PubMed
    1. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M., Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268. - DOI - PubMed
    1. Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J. The definition and classification of glaucoma in prevalence surveys. Br. J. Ophthalmol. 2002;86:238–242. doi: 10.1136/bjo.86.2.238. - DOI - PMC - PubMed
    1. Lee J.Y., Sung K.R., Kim Y.J. Association of epiretinal membrane with pseudoexfoliation glaucoma and long-term factors affecting visual function. J. Glaucoma. 2022;31:595–601. doi: 10.1097/IJG.0000000000002024. - DOI - PubMed

LinkOut - more resources